Choosing the most appropriate treatment for stable angina

Drug Safety

Volumn 19, Issue 1, 1998, Pages 23-44

  Asirvatham, Sam ^a   Sebastian, Cherian ^a   Thadani, Udho ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; NITRATE; POTASSIUM CHANNEL STIMULATING AGENT; PROBUCOL; TICLOPIDINE;

ANGINA PECTORIS; ARTICLE; ATRIOVENTRICULAR BLOCK; BLEEDING; BLOOD PRESSURE REGULATION; BRADYCARDIA; BRONCHOSPASM; CORONARY ARTERY BYPASS SURGERY; COUGHING; DIET THERAPY; DRUG TOLERANCE; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART RATE; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; NEPHROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RASH; SMOKING CESSATION; SUPRAVENTRICULAR TACHYCARDIA; SYMPTOM; WALKING;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGINA PECTORIS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTILIPEMIC AGENTS; ASPIRIN; CALCIUM CHANNEL BLOCKERS; DRUG INTERACTIONS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MYOCARDIAL INFARCTION; NITRATES; PROGNOSIS; SMOKING CESSATION; TICLOPIDINE;

EID: 0031879611     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199819010-00003     Document Type: Article

References (142)

1. Gage J, Jess D, Murakami T, et al. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris. reversibility by nitroglycerin. Circulation 1986; 73: 865-71
2. Werns SW, Walton JA, Hsia HH, et al. Evidencc of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation 1989; 79: 287-91
3. Rogers WJ, Bourassa MG, Andrews TC. Asymptomatic Cardiac Ischemia Pilot (ACIP) Study: outcome at 1 year for patients with asymptomatic cardiac ischemia randomized to medical therapy or revascularization. J Am Coll Cardiol 1995; 26: 594-605
4. Braunwald E. Sobel B. Coronary blood flow and myocardial ischemia. In: Braunwald E, editor. Heart disease: a text hook of cardiovascular medicine. Philadelphia: WB Saunders, 1988: 1191-221
5. Gillum R. Trends in acute myocardial infarction and coronary artery disease death in the United States. J Am Coll Cardiol 1993; 23: 1273-77
6. Hilton TC, Chaitman BR. The prognosis in stable and unstable angina. Cardiol Clin 1991; 9 (1) 27-38
7. The VA Coronary Artery Bypass Surgery Cooperative Study Group. Eighteen year follow up in the Veterans Affairs cooperative study of coronary artery bypass surgery for stable angina. Circulation 1992; 86: 121-30
8. Alderman EL, Bourassa MG, Cohen LS, et al. Ten year follow up of survival and myocardial infarction in the randomised coronary artery surgery study. Circulation 1990; 82: 1629-46
9. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of ten year results trom randomised trials by the coronary artery bypass graft surgery trialists collaboration. Lancet 1994; 344: 563-70
10. Jackson G: Stahle angina: drugs, angioplasty or surgery? Eur Heart J 1997; 18 Suppl. B: B2-10
11. Doll R, Peto R. Mortality in relation to smoking: 20 year observations on British doctors. Br Med J 1976; 2: 1525-36
12. Willett WC, Green A, Spampfer MJ, et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Enpl J Med 1987; 317: 1303-9
13. Manson JE, Tosteson H, Ridker PM, et al. The primary prevention of myocardial infarction. N Hngl J Med 1992; 326: 1406-16
14. Working Group for the Study of Transdermal Nicotine in Paticnts with Coronary Artery Disease. Nicotine replacement therapy for patients with coronary artery disease. Arch Intern Med 1994; 154: 989-95
15. Food and Drug Administration. Acetylsalicylic acid and the heart. JAMA 1993; 270: 2669
16. Fuster V, Dyken ML, Vokonas PS, et al. Aspirin as a therapeutic agent in cardiovascular disease. Circulation 1993; 87: 659-75
17. SAPAT (Swedish Angina Pectoris Aspirin Trial) Group, Juul-Moller S, Edvardson N, Jahnmatz B. et al. Double blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992; 340: 1421-5
18. Ridker PM, Manson JE, Gaziano M, et al. Low dose aspirin therapy for chronic stable angina: a randomised, placebo controlled trial. Ann Intern Med 1991; 114: 835-9
19. Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30mg vs 283mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325: 1261-6
20. Physicians desk reference. 52nd ed. Montvale (NJ): Medical Economics, 1998
21. Hall D, Zeitler H, Rudolph W, et al. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992; 20: 1549-55
22. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325: 293-302
23. Clelan JG, Bulpitt CJ, Falk RH, et al. Is aspirin safe in patients with heart failure? Br Heart J 1995; 74 (3): 215-9
24. Ticlopidine [editorial]. Lancet 1991; 337: 459-60
25. Kannel WB, Wilson PWF. An update on coronary risk factors. Med Clin North Am 1995; 79: 951-71
26. Rossow JE. Lipid lowering interventions in angiographie trials. Am J Cardiol 1995; 76: 86C-92C
27. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
28. Deedwania PC. Clinical perspectives on primary and secondary prevention of coronary atherosclerosis. Med Clin North Am 1995; 79: 973-98
29. Virkkunen M. Lipid Research Clinics Coronary Primary Prevention Trial Results. JAMA 1985; 253: 635-6
30. Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary artery disease of lipid-lowering diet or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992; 339: 563-9
31. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-55
32. PLAC-II Study Group, Furberg CD, Byington RP, Crouse JR, et al. Pravastatin, lipids and major coronary events. Am J Cardiol 1994; 73: 1133-4
33. Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dL) plus two additional atherosclerotic risk factors. Am J Cardiol 1993; 72: 1031-7
34. Superko HR, Drug therapy and the prevention of atherosclerosis in humans. Am J Cardiol 1989; 64: 31G-8G
35. O'Connor P, Feely J, Shepherd J. Lipid lowering drugs. BMJ 1990; 300: 667-72
36. Shepherd J, Cobbe SM, Ford J, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
37. Grundy SM. Primary prevention of coronary heart disease with drug therapy: safety and mortality issues. Arch Intern Med 1992; 152: 1369-71
38. Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during five years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996; 156: 2085-92
39. Pedersen TR, Tobert JA. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease. Drug Saf 1996; 1: 11-24
40. Bradford RH, Shear CL, Anthanassios DPH, et al. EXCEL (Expanded Clinical Evaluation of Lovastatin) study results I: efficacy in modifying plasma lipoproteins and adverse event profile in 8,245 patients with moderate hypercholesterolemia. Arch Intern Med 1991; 151: 43-9
41. World Health Organization Report. Antihyperlipidemic agents: paresthesias and neuropathy. WHO Drug Information 1993; 7: 123
42. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45
43. Carew TE. Role of biologically modified low density lipoprotein in atherosclerosis. Am J Cardiol 1989; 64: 18G-22G
44. Carbajal EV, Deedwania PC. Contemporary approaches in medical management of patients with stable coronary artery disease. Med Clin North Am 1995; 79: 1063-84
45. Milani RV, Lavie CJ. Pharmacological prevention of coronary artery disease: what do clinical trials show? Postgrad Med 1996; 99: 109-20
46. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769-75
47. Gilligan DM, Quyyumi AA, Cannon III RO. Effects of physiological levels of estrogen on coronary vasomotor function in post menopausal women. Circulation 1994; 89 (6): 2545-51
48. Karas RH, Patterson BL, Mendelsohn ME. Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 1994; 89 (5): 1943-50
49. Wagner JD, Clarkson TB, Clair RW, et al. Estrogen replacement therapy (ERT) and coronary artery (CA ) atherogenesis in surgically post menopausal cynomolgus monkeys [abstract]. Circulation 1989; 80: II-331
50. Hong MK, Romm PA, Reagan K, et al. Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in post menopausal women. Am J Cardiol 1992; 69: 176-8
51. Stampfer MJ, Colditz GA, Willen WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten year follow up from the Nurse's Health Study. N Engl J Med 1991; 325 (11): 756-62
52. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in post menopausal women. Ann Intern Med 1992; 117 (12): 1016-37
53. Sullivan JM, Van der Zwaag R, Lemp GF, et al. Post menopausal estrogen use and coronary atherosclerosis. Ann Intern Med 1988; 108: 358-63
54. Gruchow HW, Anderson AJ, Barboriak JJ, et al. Post menopausal use of estrogen and occlusion of coronary arteries. Am Heart J 1988; 115: 954-63
55. McFarland KF, Boniface ME, Hornung CA, et al. Risk factors and noncontraceptive estrogen use in women with and without coronary disease. Am Heart J 1989; 117: 1209-14
56. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in post menopausal women. N Engl J Med 1995; 332: 1589-93
57. Hennekens CH, Evans D, Peto R. Oral contraceptive use, cigarette smoking and myocardial infarction. Br J Fam Plann 1979; 5: 66-7
58. Stolley PD. Epidemiologic studies of coronary heart disease: two approaches. Am J Epidemiol 1980; 112: 217-24
59. Rich-Edwards JW, Manson JE, Hennekens CH, et al. The primary prevention of coronary heart disease in women. N Engl J Med 1995; 332: 1758-66
60. Barrett-Connor E. The menopause, hormone replacement, and cardiovascular disease: the epidemiological evidence. Maturitas 1996; 23: 227-34
61. Armitage P. Clinical trials in the secondary prevention olf myocardial infarction and stroke. Thromb Haemost 1980; 43: 90-4
62. Cauley JA, Cummings SR, Black DM, et al. Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol 1990; 163: 1438-44
63. Barrett-Connor E. Postmenopausal prevention and estrogen bias. Ann Intern Med 1991; 115: 455-6
64. Sullivan JM. Hormone replacement therapy and cardiovascular disease: the human model. Br J Obstet Gynecol 1996; 103 Suppl. 13: 59-67
65. Kafonek SD. Postmenopausal hormone replacement therapy and cardiovascular risk reduction. Drugs 1994; 47 Suppl. 2: 16-24
66. Maron DJ. Cost effective cardiology. Clin Cardiol 1996; 19: 419-23
67. Pfeffer MA,. Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 527: 669-77
68. Pepine CJ. Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function. J Am Coll Cardiol 1996; 27: 1048-52
69. Ikrarn H, Low CJS, Shirlaw TM, et al. Angiotensin converting enzyme inhibition in chronic stable angina: effect on myocardial ischemia and comparison with nifedipine. Br Heart J 1994; 71: 30-3
70. Falkenhahn M, Gohlke P, Paul M, et al. The renin-angiotensin system in the heart and vascular wall: new therapeutic aspects. J Cardiovasc Pharmacol 1994; 24 Suppl. 2: S6-13
71. Davics MK. Effects of ACE inhibition on coronary hemodynamics and angina pectoris. Br Heart J 1994; 72 Suppl.: 52-6
72. Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328: 1450-6
73. Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993; 328: 1444-9
74. Kardinaol AFM, Kok FJ, Ringstad J, et al. EURAMIC Study (European Community Multicenter Study on Antioxidants, Myocardial Infarction, and Breast Cancer): antioxidants in adipose tissue and risk of myocardial infarction. Lancet 1993; 342: 1379-84
75. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347:781-6
76. Rapola JM, Virtamo J, Ripatti S, et al. Randomised trial of alpha tocopherol and beta carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997; 349: 1715-20
77. Greenberg ER, Sporn MB. Antioxidant vitamins, cancer and cardiovascular disease. N Engl J Med 1996; 334: 1189-90
78. Kushi LH, Folsom AR, Prineas RJ, et al. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 1996; 334: 1156-62
79. Glancy DL, Richter MA, Ellis EV. Effect of swallowed isosorbide dinitrate on blood pressure, heart rate, and exercise capacity in patients with coronary artery disease. Am J Med 1997; 62: 39-46
80. Thadani U, Fung HL, Darke AC, et al. Oral isosorbide dinitrate in angina pectoris: comparison ot duration of action and dose-response relation during acute and sustained therapy. Am J Cardiol 1982; 49: 411-9
81. Thadani U, Whitsett J, Hamilton SF. Nitrate therapy for myocardial ischemic syndromes: current perspectives including tolerance. Curr Prob Cardiol 1988; 13: 725-84
82. Parker JO, Van Koughnett KA, Fung HL. Transdermal isosorbide dinitrate in angina pectorins. Am J Cardiol 1984; 54: 8-13
83. Thadani U, Opie LH. Nitrates. In: Opie LH, editor. Drugs for the heart. 4th edition. Philadelphia: WB Saunders. 1995: 31-48
84. Stamler J, Cunningham M, Loscalzo J. Reduced thiols and the effect of intravenous nitroglycerin on platelet aggregation. Am J Cardiol 1988; 6: 377-80
85. Loscalzo J. N-acetylcysteine markedly potentiates the inhibition of platelet aggregation by nitroglycerin. J Clin Invest 1985; 76: 703-8
86. Bassenge E, Stewart K. Effects of nitrates on various vascular sections on various regions. Z Kardiol 1986; 75 Suppl. 3: 1-7
87. Goldstein R, Bennet E, Leech G. Effects of glyceryl trinitrate on echocardiographic left ventricular dimensions during exercise in the upright position. Br Heart J 1979; 42: 245-54
88. Mcgregor M. Pathogenesis of angina pectoris and role of nitrates in the relief of myocardial ischemia. Am J Med 1983; 74 Suppl. 6B: 21-7
89. Thadani U, Lipicky RJ. Short and long acting oral nitrates for stable angina pectoris. Cardiovasc Drugs Ther 1994; 8: 611-23
90. Pepine CJ. Daily life ischemia and nitrate therapy. Am J Cardiol 1992; 70: 54B-63B
91. Abrams J. Management of myocardial ischemia: role of intermittent nitrate therapy. Am Heart J 1990; 120: 762-5
92. Thadani U. Role of nitrates in angina pectoris. Am J Cardiol 1992; 70: 43B-53B
93. Fung H-L, Bauer JA. Mechanisms of nitrate tolerance. Cardiovasc Drugs Ther 1994; 8: 489-99
94. Rudolph W, Dirschinger J, Reiniger G, et al. When does nitrate tolerance develop?: what dosages and which intervals are necessary to ensure maintained effectiveness? Eur Heart J 1988; 9 Suppl. A: 63-72
95. Thadani U, Lipicky RJ. Ointments and transdermal nitroglycerin patches for stable angina pectoris. Cardiovasc Drugs Ther 1994; 8: 625-33
96. Thadani U. Strategies for avoiding nitrate tolerance in stable angina patients. Cardiology 1994; 45-7
97. Chrysant SG, Glasser SP, Bittar N, et al. Efficacy and safety of extended release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol 1993; 72: 1249-56
98. Parker JO, The Isosorbide-5-Mononitrate Study Group. Eccentric dosing with isosorbide-5-mononitrate in angina pecloris. Am J Cardiol 1993; 72: 871-6
99. Thadani U, Maranda CR, Amsterdam E, et al. Lack of pharmacologic tolerance and rebound angina pectoris during twice daily therapy with isosorbide-5-mononitrate. Ann Intern Med 1994; 120: 353-9
100. Thadani U. Nitrate tolerance, rebound and their clinical relevance in stable angina pectoris, unstable angina and heart failure. Cardiovasc Drugs Ther 1996: 10: 735-42
101. Alpert JS. Nitrate therapy in the elderly. Am J Cardiol 1990; 65: 23J-7J
102. Opie LH, Sonnenblick EH, Frishman W, et al. Beta blocking agents. In: Opie LH, editor. Drugs for the heart. 4th ed. Philadelphia: WB Saunders, 1995: 1-27
103. Goldstein S. Betablockers in hypertensive and coronary heart disease. Arch Intern Med 1996; 156: 1267-76
104. Raftry EB. The preventative effects of vasodilating betablockers in cardiovascular disease. Eur Heart J 1996; 17 Suppl. B: 30-8
105. Goldstein S. Propranolol therapy in patients with acute myocardial infarction: the beta-blocker heart attack trial. Circulation 1983; 67 Suppl. I: 153-6
106. Thadani U, Whitsett TL. Beta adrenergic blockers and intermittent claudication. Arch Intern Med 1991; 151: 1705-7
107. Covinsky JO. New therapeutic modalities for the treatment of elderly patients with ischemic heart disease. Am J Med 1987; 82 Suppl. 1B: 41-6
108. Wassertheil-Smoller S, Oberman A, Blaufox MD. The Trial of Antihyperteasive Interventions and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk, and quality of life. Am J Hyperten 1992; 5: 37-44
109. Thadani U. Assessment of 'optimal' beta-blockade in treating patients with angina pectoris. Acta Med Scand 1985; 694 Suppl.: 179-87
110. Thadani U, Classer S, Bittar N, et al. Dose-response evaluation of once-daily therapy with a new formulation of diltiazem for stable angina pectoris. Am J Cardiol 1994; 74: 9-17
111. Follath F. The role of calcium antagonists in the treatment of myocardial ischemia. Am Heart J 1989; 118: 1093-7
112. Weiner DA. Calcium channel blockers. Med Clin North Am 1988; 72 (1): 83-114
113. Opie LH. Calcium channel antagonists in the treatment of coronary artery disease: fundamental pharmacological properties relevant to clinical use. Prog Cardiovasc Dis 1996; 38 (4): 273-90
114. Hermsmeyer K, Mishra S, Miyagawa K. et al. Physiologic and pathophysiologic relevance of T-type calcium-ion channels: potential indications for T type calcium antagonists. Clin Ther 1997; 19 Suppl. A: 18-26
115. Bakx AL, van der Wall EE, Braun S, et al. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study: Ro 40-5967 International Study Group. Am Heart J 1995; 130 (4): 748-57
116. Trivoni D, Kadr H, Braat S, et al. Efficacy of mibefradil compared with amlodipine in suppressing exercise induced and daily silent ischemia: results of multicenter, placebo controlled trial. Circulation 1997; 96: 2557-67
117. Opie LH, Frishman WH, Thadani H. Calcium channel antagonists (calcium entry blockers). In: Opie LH, editor. Drugs for the heart. 4th ed. Philadelphia: WB Saunders, 1995: 50-82
118. Zema MJ, Perlmutter S, Mankes S, et al. Diltiazem treatment for the management of ischemia in patients with poor left ventricular function: safety of long term administration. Br Heart J 1987; 58: 512-17
119. Remme WJ, Krauss XH, van Hoogenhuyze DCA, et al. Hemodynamic tolerability and anti-ischemic efficacy of high dose intravenous diltiazem in patients with normal versus impaired ventricular function. J Am Coll Cardiol 1993; 21: 709-20
120. Conti CR. The calcium antagonist scare in America: what have we learned? Clin Cardiol 1996; 19: 345-6
121. Taylor SH. The efficacy of amlodipine in myocardial ischemia. Am Heart J 1989; 118: 1123-30
122. Lopez LM, Santiago TM. Isradipine: another calcium-channel blocker for the treatment of hypertension and angina. Ann Pharmacother 1992; 26: 789-99
123. Singh BN. Comparative efficacy and safety of hepridil and diltiazem in chronic stable angina pectoris refractory to diltiazem. Am J Cardiol 1991; 68: 306-12
124. Frampton J, Buckley MM, Fitton A. Nicorandil: a review of its pharmacology and therapeutic efficacy in angina pectoris. Drugs 1992; 44: 625-55
125. Thadani U, Strauss W, Glasser SP, et al. Evaluation of antianginal and anti ischemic efficacy of nicorandil; results of a multicenter study [abstract]. J Am Coll Cardiol 1994; I: 267A
126. Meany TB, Richardson P, Camm AJ, et al. Exercise capacity after single and twice-daily doses of nicorandil in chronic stable angina pectoris. Am J Cardiol 1989; 63: 66J-70J
127. Brown CM, Clarke B, Dye A, et al. Pharmacological profile of ranolozine, a metabolic modulator active in ischemia [abstract]. Br J Pharmacol 1988; Suppl.: 248
128. Jain D, Dasgupta P, Hughes LO, et al. Ranolazine (RS-43285) a preliminary study of a new antianginal agent with selective effect on ischemic myocardium. Eur J Clin Pharmacol 1990; 38:111-4
129. Essamri B, Rousseau MF, D'Houdt AM, et al. Novel antianginal agent increases exercise duration and pressure-rate product in patients receiving diltiazem or betablocker [abstract]. Circulation 1990; 82 Suppl. III: III-399
130. Jain D, Lahiri A, Dasgupta P, et al. RS 43285 (Syntex): a preliminary study of a unique antianginal agent [abstract]. Clin Sci 1987; 73 Suppl. 17: 38P
131. Cocco G, Rousseau MF, Bouvy T, et al. Effect of a new metabolic modulator, ranolazine on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol 1992; 20: 131-8
132. Thadani U, Ezekowitz M. Fenney L. et al. Double blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Circulation 1994; 90: 726-34
133. Quyyumi AA, Crake T, Wright CM, et al. Medical treatment of patients with severe exertional and rest angina: double blind comparison of betablocker, calcium antagonists, and nitrate. Br Heart J 1987; 57: 505-11
134. Thadani U. Medical therapy of stable angina pectoris. Cardiol Clin 1991; 9 (1): 73-88
135. Thadani U, Chohan A. Chronic stable angina pectoris: strategies for effective drug therapy. Postgrad Med 1995; 98 (6): 175-88
136. Strauss WE, Parisi AF. Combined use of calcium channel and betablockers for the treatment of stable angina; rationale, efficacy and adverse effects. Ann Intern Med 1988; 109: 570-75
137. Packer M, Drug therapy: combined beta-adrenergic and calcium entry blockade in angina pectoris. N Engl J Med 1989; 320: 709-13
138. Thadani U. Combination therapy for the angina patient. J Am Coll Cardiol 1989; 5: 15-9
139. Tolins M, Weir EK, Chesler E, et al. Maximal drug therapy is not necessarily optimal in chronic angina pectoris. J Am Coll Cardiol 1984; 4: 1051-7
140. Akhras F, Jackson G, Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. Lancet 1991; 338: 1036-39
141. Thadani U. Comhination therapy. ACC Curr J Rev 1997; 6: 24-5
142. Management of stable angina pectoris: recommendations of the task force of the European Society of Cardiology. Eur Heart J 1997; 18: 394-413